Drug Trial Radar · NCT05672121
Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Last checked: Nov 19, 2026Latest source record: Nov 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Feb 6, 2023
Primary completion
Dec 28, 2026
Study completion Dec 28, 2026
Sponsor
- Lead sponsor
- Chengdu Origen Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 5, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
KH631 is a adeno-associated virus (AAV) vector-based gene therapy for subretinal injection. The long-term, stable therapeutic protein after one time injection for nAMD could potentially reduce the treatment burden and maintain vision.
Conditions
- Age-Related Macular Degeneration
Interventions
KH631Drug
KH631: AAV vector containing a coding sequence for an anti-VEGF protein
Primary outcomes
What the sponsor says the trial is designed to measure.
- SafetyTime frame: 24 weeks
- Change in best corrected visual acuityTime frame: 52 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tongren Hospital, Capital Medical University
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.